Churg-Strauss syndrome: Still a clinical challenge

Expert Review of Clinical Immunology

Volumn 3, Issue 6, 2007, Pages 833-837

  Rolla, Giovanni ^a   Guida, Giuseppe ^a   Heffler, Enrico ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DEATH RECEPTOR; DEATH RECEPTOR 3; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; VASCULOTROPIN;

ANCA ASSOCIATED VASCULITIS; ASTHMA; AUTOPSY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHURG STRAUSS SYNDROME; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EDITORIAL; EOSINOPHILIA; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFILTRATE; PATHOGENESIS; RISK FACTOR; SINUSITIS; T LYMPHOCYTE; VASCULITIS;

EID: 36249014342     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.6.833     Document Type: Editorial

References (28)

1. Churg J, Strauss L. Allergic angiitis and periarteritis nodosa. Am. J. Pathol. 27, 277-301 (1951).
2. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 63, 65-81 (1984).
3. Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 33, 1094-1100 (1990).
4. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 37, 187-192 (1994).
5. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann. Rheum. Dis. 66, 222-227 (2007).
6. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N. Engl. J. Med. 299, 926-930 (1978).
7. Sinico RA, Di Toma L, Maggiore U et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 52, 2926-2935 (2005).
8. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID) J. Allergy Clin. Immunol. 113, 11-28 (2004).
9. Rolla G, Tartaglia N, Motta M et al. Warning nonrespiratory symptoms in asthma: catastrophic abdominal involvement in a case of Churg-Strauss syndrome. Ann. Allergy Asthma Immunol. 98, 595-597 (2007).
10. Ramakrishna G, Midthun DE. Churg-Strauss syndrome. Ann. Allergy Asthma Immunol. 86, 603-613 (2001).
11. Rolla G, Heffler E, Guida G et al. Exhaled nitric oxide in diffuse alveolar haemorrhage. Thorax 60, 614-615 (2005).
12. Mitsuyama H, Matsuyama W, Watanabe M et al. Increased expression of TRAIL receptor 3 on eosinophils in Churg-Strauss syndrome. Arthritis Rheum. 56, 672-683 (2007).
13. Mitsuyama H, Matsuyama W, Iwakawa J et al. Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome. Chest 129, 407-411 (2006).
14. Taira T, Matsuyama W, Mitsuyama H et al. Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin. Exp. Immunol. 148, 241-247 (2007).
15. Schmitt WH, Csernok E, Kobayashi S et al. Churg-Strauss syndrome: serum markers of of lymphocytic activation and endpothelial damage. Arthritis Rheum. 41, 4445-4452 (1998).
16. Müschen M, Warskulat U, Perniok A et al. Involvement of soluble CD95 in Churg-Strauss syndrome. Am. J. Pathol. 155, 915-925 (1999).
17. Chen R, Sakamoto M, Ikemoto K, Abe R, Shimizu H. Granulomatous arteritis in cutaneous lesions of Churg-Strauss syndrome. J. Cutan. Pathol. 34, 330-337 (2007).
18. Hattori N, Ichimura N, Nagamatsu M et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 122, 427-439 (1999).
19. Kiene M, Csernok E, Muller A, Metzler C, Trabandt A, Gross WL. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum. 44, 469-473 (2001).
20. Griffith ME, Coulthart A, Pusey CD. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin. Exp. Immunol. 103, 253 (1996).
21. Serna-Candel C, Moreno-Perez O, Soriano V, Martinez A. Churg-Strauss syndrome triggered by hyposensitization to Alternaria fungus. Clin. Rheumatol. (2007) (Epub ahead of print).
22. Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case-control study, Arthritis Rheum. 48, 814-823 (2003).
23. Tervaert JW, Popa ER, Bos NA. The role of superantigens in vasculitis. Curr. Opin. Rheumatol. 11, 24-33 (1999).
24. Guida G, Heffler E, Cignetti A et al. T cell Vβ clonal expansion with a Th1 phenotype in Churg Strass sindrome. Prestented at: XXV Congress of the European Academy of Allergology and Clinical Immunology. Vienna, Austria, 10-14 June 2006 (Abstract 317).
25. Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A et al. Oligoclonal T cell expansions in patients with Behcet's disease. Clin. Exp. Immunol. 117, 166-170 (1999).
26. Mayo MJ, Jenkins RN, Combes B et al. Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma. Hepatology 29, 1635-1642 (1999).
27. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214-224 (2006).
28. Lamprecht P, Csernok E, Gross WL. Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis. J. Intern. Med. 260, 187-191 (2006).